Webinar: Knowledge - Based Drug Repositioning

Sponsored by: Thomson Reuters

Focused on:

Date: 8th November

Days old: 4472

Time: 3PM London/10AM New York

Watch Now for FREE

Driving R&D success and reducing development timelines and costs

Repositioning of launched or failed drugs has opened up a new source of revenue to large, medium, and small Pharma companies, helping to offset R&D productivity challenges. In 2012, drug repositioning is expected to generate up to $20 billion in annual sales within the industry.

Apart from the opportunity to create commercial value, drug repositioning has a number of R&D advantages including:

  • Reduction of R&D timelines by up to 3-5 years
  • Reduced development costs (due to sunk research costs and in many cases the availability of clinical safety, tolerability, and efficacy data)
  • Improved probability of success



This webinar investigates how improved access to high quality data and world class analytical capabilities have driven companies’ abilities to reposition existing assets into new diseases. We will discuss how the business of drug repositioning has been transformed from an opportunistic approach to a scientifically robust and logical process for finding new uses for drugs in well defined and selected patient populations.

We look at the process by which a blockbuster can be produced by combining repositioning and personalized medicine strategies. We investigate how an initial approval in a small, well defined patient group, can be followed with a series of repositioning opportunities to build a blockbuster incrementally.

Complementing our recent white paper, this webinar will examine current strategies being employed, industry findings and the merits of a knowledge-based approach to drug repositioning. This will be placed into a real-world setting using a detailed case study of how we have worked with a top Pharma company to accelerate their repositioning activities.

Presented by

Richard Harrison,

Discovery Practice Director, Life Sciences Professional Services, Thomson Reuters

Dr. Richard K. Harrison is Discovery Practice Director in the Thomson Reuters Professional Services group. He has over 30 years of experience in the life sciences industry. His career has focused on all aspects of pre-clinical drug discovery. During this time he has held positions of increasing responsibility at Aventis, Merck, DuPont and Wyeth Pharmaceuticals where he delivered numerous clinical candidates and worked on several marketed drugs. In addition, he served as a founding scientist in two successful venture funded computational and structure based drug design companies. Dr. Harrison has authored over 40 peer reviewed publications and book chapters in all areas of drug discovery and has presented over 50 invited lectures on these subjects. He earned his Ph.D. in Biophysical Chemistry and Enzymology and currently serves as an adjunct professor at several universities.

Svetlana Bureeva,

Director, Life Sciences Professional Services, Thomson Reuters

Sveta Bureeva is a Director within the Thomson Reuters Life Sciences Professional Services team. With more than 6 years' experience in the life sciences sector, she has a background in systems biology and its application for data analysis.

Sveta holds a masters in Biotechnology and a PhD in Biochemistry. Following her academic studies, Sveta joined GeneGo, now a Thomson Reuters company, where she gained experience leading the chemistry group to develop chemical content and analytical tools for chemical research. She now leads knowledge management services related to systems biology information and is involved in development of drug repositioning methods based on applications of pathway analysis.

Download Slides

Please login to download the slides

Key Learning Objectives

  • How drug repositioning is developing within the industry
  • Knowledge-based approaches to drug repositioning
  • Combining strategies for faster approval

Audience

  • Leaders of Drug Positioning Units
  • Heads of Therapy Areas
  • VPs of R&D
  • Heads of Informatics
  • Heads of Brand and all those interested in exploring drug repositioning